Legend Biotech

At Legend, patient commitment doesn’t pause for the weather. Patients are waiting, and every day matters.   Despite severe winter conditions, our #CART #CellTherapy team in Raritan, home to Legend and Johnson & Johnson Innovative Medicines operations, continued around‑the‑clock operations without interruption, while prioritizing employee safety.   To keep our teams safe, supported, and operational, leaders secured local hotel accommodations, arranged shuttle transportation, provided onsite meals for every shift, stocked break rooms with emergency supplies, and managed countless behind‑the‑scenes efforts.   With LEGENDary leadership from Ketan Gujarathi Kim Soika, CSP, Elaine Kwon, and Anthony Gonzalez, our teams stayed safe, connected, and focused on what matters most: delivering hope to patients.

In a recent article by the Society of Hematologic Oncology Insider, our CEO, Ying Huang, reflects on the evolution of our #CART #CellTherapy from the first U.S. patient treated for #MultipleMyeloma in China to the global collaboration with Johnson & Johnson Innovative Medicine, and the long-term research that followed.   The piece highlights our groundbreaking five-year survival data, leading some physicians to cautiously discuss the possibility of a “cure” for a subset of patients with multiple myeloma, while underscoring the need for continued follow-up and broader evidence. 🔗 Read more: https://lnkd.in/g57-AZFF   #CancerResearch #HealthcareInnovation

Join us next month in Salt Lake City for the #Tandem26 Meetings hosted by ASTCT and CIBMTR (Center for International Blood & Marrow Transplant Research)!   Six poster presentations will highlight the efficacy, safety, and real-world outcomes of our #CART #CellTherapy, derived from the CARTITUDE trials and analyses, reinforcing the growing body of evidence supporting earlier use in the #MultipleMyeloma treatment journey.   If you’re attending, stop by booth #301 to meet the team and learn more about our poster presentations. https://lnkd.in/ggRXxrN4

An updated analysis from the CARTITUDE-4 study, published in The Lancet Oncology, a journal of The Lancet Group, reports outcomes evaluating earlier use of our #CART #CellTherapy for #MultipleMyeloma. These findings add to the growing body of clinical evidence being explored to inform treatment decisions and future research, underscoring our commitment to advancing impactful treatments for patients.   🔗 Read the publication: https://lnkd.in/gK7VDPtv

#LegendNews: We’re proud to share that more than 10,000 patients worldwide have been treated with our #CART #CellTherapy since its initial approval.   This milestone reflects our impact on thousands of lives and the trust placed in us by patients and clinicians. It is made possible by the dedication of our research, manufacturing, and #Patient care teams.   Thank you to our partner Johnson & Johnson Innovative Medicine, alongside investigators, nurses, caregivers – most importantly, the patients and families who inspire us every day. Together, we are forging a path to a cure.    #PatientsFirst #WeAreLegend https://lnkd.in/gut7u6Qe

We’re proud to share that our CEO, Ying Huang, has been named to the OncoDaily 100 List, recognizing leaders driving progress in #Oncology. This honor reflects Ying’s vision and leadership, as well as our collective commitment to advancing bold #Science, delivering innovative #CellTherapies, and transforming outcomes for patients living with #Cancer. Congratulations to all #OncoDaily100 honorees who are making significant strides in collaboration across the oncology community. https://lnkd.in/gmJBfE6h

Next week, our team will be on site at the J.P. Morgan Healthcare Conference in #SanFrancisco. Our CEO, Ying Huang, will present on January 14 at 9 a.m. PT, sharing how Legend is building momentum across our #Innovative pipeline, advancing #Patient access, and scaling our global footprint in #CellTherapy. Learn more and register: https://lnkd.in/gekymAU #JPMorganHealthcare #JPM26

Researchers from Legend Biotech will share updated data on LB1908, our CAR-T #CellTherapy targeting Claudin 18.2, in a poster presentation at the 2026 ASCO Gastrointestinal Cancers Symposium in San Francisco! 🗓 Thursday, January 8, 2026 ⏰ 11:30 a.m.–1:00 p.m. PST 📍 Level 1, West Hall 🧾 Abstract 374 | Poster D5 The presentation will cover response rates, safety, and CAR-T expansion kinetics. We look forward to engaging with the #GI26 community. 🔗 View session details: https://lnkd.in/g_qtFMZi

As we close out the year, we’re proud of the progress made across our science, our manufacturing network, and our global teams. Our CEO, Ying Huang, shares his thoughts. #WeAreLegend

During this holiday season, we’re taking a moment to reflect on what truly drives us – the people behind our progress. We are grateful to all our #LEGENDary colleagues for their tireless dedication, teamwork, and shared belief in the power of #Science to change lives. #WeAreLegend #CompanyCulture